NCT06355531: An ongoing trial by Ferrer Internacional S.A.
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06355531 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 23, 2024 |
| Completion date | Nov. 30, 2026 |
| Required reporting date | Nov. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |